JRK

Across TCGA pan-cancer cohorts, JRK Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JRK data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher JRK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JRK expression acts as an unfavorable survival marker.

THYM, HNSC, and KICH are the cancer types where JRK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	OS	Median	II,III,IV	0.086	0.711	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
READ	DFS	Median	III,IV	0.182	0.745	.007	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	DFS	Median	III,IV	0.044	0.597	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JRK–THYM (OS)

Open the THYM breakdown →